ROSEN, A TOP RANKED LAW FIRM, Encourages TG Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - TGTXNewsfile Corp • 08/05/22
SHAREHOLDER ACTON ALERT: The Schall Law Firm Encourages Investors in TG Therapeutics, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 08/05/22
TG Therapeutics to Host Conference Call on Second Quarter 2022 Financial Results and Business UpdateGlobeNewsWire • 08/05/22
TG THERAPEUTICS INC. Company News: Berger Montague Investigates Securities Fraud Allegations Against TG Therapeutics Inc. (NASDAQ: TGTX); Lead Plaintiff Deadline is September 16 2022PRNewsWire • 08/04/22
TGTX SECURITIES FRAUD: Hagens Berman, National Trial Attorneys, Encourages TG Therapeutics (TGTX) Investors with Losses to Contact Firm's Attorneys, Securities Class Action PendingNewsfile Corp • 08/04/22
Bronstein, Gewirtz & Grossman, LLC Notifies TG Therapeutics, Inc. (TGTX) Investors of Class Action and Encourages Investors to Contact the FirmNewsfile Corp • 08/03/22
TGTX ALERT: Hagens Berman, National Trial Attorneys, Encourages TG Therapeutics (TGTX) Investors with Losses to Contact Firm's Attorneys, Securities Class Action FiledPRNewsWire • 08/03/22
ROSEN, National Trial Lawyers, Encourages TG Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - TGTXNewsfile Corp • 08/02/22
TGTX Shareholder News: Robbins LLP is Investigating TG Therapeutics, Inc. (TGTX) on Behalf of ShareholdersBusiness Wire • 08/01/22
ROSEN, Leading Investor Counsel, Encourages TG Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TGTXNewsfile Corp • 07/28/22
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages TG Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - TGTXNewsfile Corp • 07/23/22
TGTX Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against TG Therapeutics, Inc. (TGTX)Business Wire • 07/22/22
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages TG Therapeutics, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - TGTXPRNewsWire • 07/22/22
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against TG Therapeutics, Inc. (TGTX)Business Wire • 07/20/22
TG THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against TG Therapeutics, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 07/20/22
EQUITY ALERT: Rosen Law Firm Encourages TG Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – TGTXBusiness Wire • 07/18/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors TG Therapeutics, Inc. - TGTXPRNewsWire • 06/28/22
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of NeurologyGlobeNewsWire • 06/27/22
TG Therapeutics (TGTX) Soars 18.7%: Is Further Upside Left in the Stock?Zacks Investment Research • 06/09/22
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Annual MeetingGlobeNewsWire • 06/03/22
TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMSGlobeNewsWire • 05/31/22
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual MeetingGlobeNewsWire • 05/26/22